News

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain people with chronic obstructive pulmonary disease (COPD). The treatment, from GSK, is specifically indicated for adults with COPD whose disease is not adequately controlled with other therapies and who have…

Using e-cigarettes, often called vaping, significantly increases the risk of chronic obstructive pulmonary disease (COPD), a U.S. study suggests. People who used e-cigarettes, which are battery-powered devices that heat a liquid that typically contains nicotine to produce an inhalable aerosol, alone were more than twice as likely to develop…

Wellinks, which bills itself as a digital healthcare company, has announced that it will partner with Careabout Health to introduce its virtual chronic obstructive pulmonary disease (COPD) management program to the New Jersey and Florida markets. The COPD management program involves virtual pulmonary rehabilitation, remote monitoring,…

A digital, community-based intervention to treat chronic obstructive pulmonary disease (COPD) exacerbations in a home setting significantly improved the quality of life of patients, a pilot study suggests. The Healthy at Home intervention combined biometric monitoring via a smartwatch, symptom tracking, mobile on-demand acute care services, and optional digital…

Lower respiratory diseases including chronic obstructive pulmonary disease (COPD) were the sixth leading cause of death in the U.S. in 2022, accounting for 4.5% of all deaths registered that year. That’s according to a report, “Deaths: Leading Causes for 2022,” released by the U.S. Centers for Disease Control and…

A urine test developed in a dipstick format by Global Access Diagnostics helped not only distinguish between stable and exacerbation states among chronic obstructive pulmonary disease (COPD) patients but also was able to predict exacerbations a week in advance. That’s according to the results of a new study…

Oral supplementation with nicotinamide riboside, a form of vitamin B3, helped reduce markers of lung inflammation in older adults with chronic obstructive pulmonary disease (COPD), data from a placebo-controlled study shows. The benefits were sustained for at least three months after supplementation ended. These findings are “significant, because inflammation…

The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases marked by type 2 inflammation. KT-621 is designed to target STAT6, a protein involved in type 2 inflammation, which…

Ohtuvayre (ensifentrine), an inhaled therapy approved in the U.S. earlier this year for adults with chronic obstructive pulmonary disease (COPD), has been found to safely and effectively lead to clinical improvements among COPD patients regardless of disease severity, smoking history, and chronic bronchitis history. Chronic bronchitis is a…